
CLAIMS

1. An antisense oligomer compound of formula (III):



(III) ,

or a pharmaceutically acceptable salt thereof, wherein:

each Nu is a nucleobase which taken together form a targeting sequence (5' to 3') selected from:

a) SEQ ID NO: 3 (CTGAGCCGCTGGCAGATGCCTTGTC) wherein Z is 23; and


b) SEQ ID NO: 4 (GAGGAGATGGGTCCACCCACCTGGG) wherein Z is 23;

wherein R^a is acetyl.

2. The antisense oligomer compound of claim 1, wherein the target sequence is SEQ ID NO: 3 (CTGAGCCGCTGGCAGATGCCTTGTC) and Z is 23.

3. The antisense oligomer compound of claim 1, wherein the target sequence is SEQ ID NO: 4 (GAGGAGATGGGTCCACCCACCTGGG) and Z is 23.


4. The antisense oligomer compound of claim 1, wherein the antisense oligomer compound is a compound of formula (IV):



(IV)

or a pharmaceutically acceptable salt thereof, wherein each Nu is a nucleobase which taken together form a targeting sequence (5’ to 3’) wherein the targeting sequence is SEQ ID NO: 3 (CTGAGCCGCTGGCAGATGCCTTGTC) and Z is 23.


5. The antisense oligomer compound of claim 1, wherein the antisense oligomer compound is a compound of formula (IV):



(IV)


or a pharmaceutically acceptable salt thereof, wherein each Nu is a nucleobase which taken together form a targeting sequence (5’ to 3’) wherein the targeting sequence is SEQ ID NO: 4 (GAGGAGATGGGTCCACCCACCTGGG) and Z is 23.

6. An antisense oligomer compound, or a pharmaceutically acceptable salt thereof, selected from:



(V a)


; and



(V b)

.


7. The antisense oligomer compound of claim 6, wherein the antisense oligomer compound is:



(V a)

.


8. The antisense oligomer compound of claim 6, wherein the antisense oligomer compound is:



(V b)


.

9. An antisense oligomer compound, or a pharmaceutically acceptable salt thereof, selected from:



(VI a)

; and



(VI b)

.

10. The antisense oligomer compound of any one of claims 1-9, wherein the antisense oligomer compound is a pharmaceutically acceptable salt of 0.6 HCl.

11. A pharmaceutical composition, comprising an antisense oligomer compound according to any one of claims 1-10 and a pharmaceutically acceptable carrier.

12. Use of an antisense oligomer compound according to any one of claims 1-10 or the pharmaceutical composition of claim 11 in the manufacture of a medicament for the treatment of Hutchinson- Gilford progeria syndrome (HGPS).